ライフサイエンスコーパス: renal insufficiency

1 (diabetes mellitus, atrial fibrillation, and renal insufficiency).

2 ed grade 3 dose-limiting toxicity (seizures, renal insufficiency).

3 3 with 4306 lithium-exposed patients without renal insufficiency.

4 , in skin samples of patients suffering from renal insufficiency.

5 ns including hypertrophic cardiomyopathy and renal insufficiency.

6 a on patients with severe (stage 4 to 5 CKD) renal insufficiency.

7 or whether patients had diabetes mellitus or renal insufficiency.

8 phrogenic systemic fibrosis in patients with renal insufficiency.

9 ibrosis in MRI contrast-treated rodents with renal insufficiency.

10 dings in irritable bowel syndrome and severe renal insufficiency.

11 ((99m)Tc-MAG3) scintigraphy in patients with renal insufficiency.

12 ion, arterial stiffening, heart failure, and renal insufficiency.

13 e for chronic diseases, namely, diabetes and renal insufficiency.

14 of the parathyroid gland after the onset of renal insufficiency.

15 e elderly, pregnant women, and patients with renal insufficiency.

16 buse and suffered relapse of proteinuria and renal insufficiency.

17 ibrosing disorder occurring in patients with renal insufficiency.

18 ears or 50 to 60 years with hypertension and renal insufficiency.

19 atic liver disease), antibiotic therapy, and renal insufficiency.

20 for renal toxicity and the dose modified for renal insufficiency.

21 nt-specific risk of developing postoperative renal insufficiency.

22 on who are at high risk of developing severe renal insufficiency.

23 , symptomatic carotid stenosis, and baseline renal insufficiency.

24 s population and precedes the development of renal insufficiency.

25 hypertension is uncommon in SS disease with renal insufficiency.

26 osing entity of the skin in association with renal insufficiency.

27 es and is a major cause of acute and chronic renal insufficiency.

28 uscle mass, may be insensitive for detecting renal insufficiency.

29 as coronary disease, diabetes mellitus, and renal insufficiency.

30 pulse pressure seen with age, diabetes, and renal insufficiency.

31 heral arterial disease (PAD) in persons with renal insufficiency.

32 ation to computed tomography contrast due to renal insufficiency.

33 c lupus erythematosus such as leukopenia and renal insufficiency.

34 ical and public health importance of chronic renal insufficiency.

35 to be examined, especially in the setting of renal insufficiency.

36 tly associated with all comorbidities except renal insufficiency.

37 particularly in these patients who may have renal insufficiency.

38 tients exhibiting mild to moderate or severe renal insufficiency.

39 syndrome (PTMS), cardiovascular events, and renal insufficiency.

40 No participants experienced renal insufficiency.

41 tting of drug initiation and the presence of renal insufficiency.

42 lly approved for use in patients with severe renal insufficiency.

43 ion of their function, eventually leading to renal insufficiency.

44 lications in the clinical setting of chronic renal insufficiency.

45 y of diagnosis, even in pregnancy and severe renal insufficiency.

46 ncy]; and OR 1.52, CI 1.32 to 1.76 [moderate renal insufficiency]).

47 s calculated using 0.0398 x (age) + 0.516 x (renal insufficiency) + 0.46 x (previous cerebrovascular

48 tion (6), intussusception (2), and transient renal insufficiency (1).

49 .5% vs 3.8%), diabetes (18.7% vs 11.1%), and renal insufficiency (1.7% vs 1.3%).

50 gical targets (24%), advanced age (16%), and renal insufficiency (16%).

51 litus (45.5% versus 30.8%; P<0.001), chronic renal insufficiency (19.2% versus 10.7%; P<0.001), and c

52 unction before CABG surgery developed severe renal insufficiency (229/8363).

53 es included coronary artery disease (51.5%), renal insufficiency (27.4%), diabetes mellitus (29.5%),

54 fraction <40% [4 points], anemia [2 points], renal insufficiency [3 points], triple-vessel disease [2

55 damage in SCA and the clinical correlates of renal insufficiency, 300 adult patients with SCA were st

56 nsion (77% versus 65%; P=0.006), and chronic renal insufficiency (34% versus 19%; P<0.0001).

57 abetes (58%), tobacco use (52%), and chronic renal insufficiency (39%).

58 % CI, 47.7%-69.4%]) and patients with severe renal insufficiency (62.5% [99% CI, 59.9-65.0]).

59 i syndrome (38%; all with crystalline LCPT), renal insufficiency (83%), and proteinuria (98%).

60 lin-requiring diabetes mellitus and baseline renal insufficiency, a greater overall burden of coronar

61 nce interval [CI]: 1.01 to 1.04; p < 0.001), renal insufficiency (adjusted HR: 1.48; 95% CI: 1.07 to

62 I, 1.06-1.38), and with having no history of renal insufficiency (adjusted OR, 0.85; 95% CI, 0.75-0.9

63 Renal insufficiency after coronary artery bypass graft (

64 Sirolimus is used in patients with renal insufficiency after liver transplantation (LT) and

65 ocognitive dysfunction after OPCAB, and less renal insufficiency after OPCAB.

66 - 35.34); hemorrhage (aHR 4.92, 1.28-18.94); renal insufficiency (aHR 4.85, 1.20 - 19.61); inadequate

67 including "chronic kidney disease", "chronic renal insufficiency", "albuminuria", "proteinuria", and

68 ment in renal function in LT recipients with renal insufficiency, although the results are limited by

69 renal function of patients who have chronic renal insufficiency, although these agents do not affect

70 hrombosis, a body weight >/=100 kg, moderate renal insufficiency, an age >/=75 years, and cancer.

71 elevant skeletal disease was associated with renal insufficiency and above 10-fold elevated fluoride

72 Renal insufficiency and advanced age were strongly assoc

73 The relationship between renal insufficiency and amino-terminal pro-brain natriur

74 rted almost exclusively in patients who have renal insufficiency and are exposed to contrast media fo

75 gated the relationship between pre-operative renal insufficiency and disease prognosis.

76 Heart failure patients with renal insufficiency and diuretic resistance have increas

77 ged echogenic kidneys, ultimately leading to renal insufficiency and end-stage renal disease.

78 riconazole, 300 mg twice daily, secondary to renal insufficiency and eventually continued treatment w

79 r CLKT by using three variables: duration of renal insufficiency and glomerular filtration rate measu

80 therapy until surgery is beneficial, whereas renal insufficiency and left main disease increase the r

81 ously known risk factors for mortality, like renal insufficiency and leukocytosis, the network identi

82 Renal insufficiency and LMD were independent predictors

83 urged to limit their potassium intake during renal insufficiency and may adhere to this principle aft

84 We sought to explore the association between renal insufficiency and mortality among women with heart

85 ction did not modify the association between renal insufficiency and mortality risk, but the use of a

86 e potential for exacerbating hypertension or renal insufficiency and possible interactions with angio

87 tion due to bleeding, prolonged ventilation, renal insufficiency and primary graft dysfunction.

88 lantation (LT), but the role of pre-existing renal insufficiency and proteinuria remains unclear amon

89 cations compared with those who did not have renal insufficiency and received a full dose.

90 njury in neutropenic mice resulted in milder renal insufficiency and significantly reduced mortality,

91 rkedly ameliorates albuminuria and abrogates renal insufficiency and the diabetic nodular glomerulosc

92 may be warranted in patients with underlying renal insufficiency and those who develop renal insuffic

93 2 showed decreased efficacy in patients with renal insufficiency, and 1 showed increased mortality co

94 ntation, 49% had nephrotic syndrome, 68% had renal insufficiency, and 77% had hematuria.

95 ns of natriuretic peptides, mild-to-moderate renal insufficiency, and a systolic blood pressure of at

96 affected, history of heart failure (HF), or renal insufficiency, and by CART analysis were those wit

97 pressure, hypercholesterolemia, dysglycemia, renal insufficiency, and cognitive impairment.

98 ys), post-operative ventricular arrhythmias, renal insufficiency, and development of protein-losing e

99 Sema3a(+) mice develop massive proteinuria, renal insufficiency, and extensive nodular glomeruloscle

100 ucts, systemic hypertension, and progressive renal insufficiency, and in the liver with biliary dysge

101 ent predictors of complications include age, renal insufficiency, and individual operator.

102 uding hemodilution, inflammatory activation, renal insufficiency, and malnutrition.

103 uch as circulatory failure, volume overload, renal insufficiency, and respiratory failure.

104 terminal prohormone of BNP, mild-to-moderate renal insufficiency, and systolic blood pressure greater

105 terminal prohormone of BNP, mild-to-moderate renal insufficiency, and systolic blood pressure greater

106 wound infection, myocardial infarction, and renal insufficiency, and the rates of these complication

107 ortality risk is increased in the setting of renal insufficiency, and the two most important risk pre

108 lower hemoglobin and creatinine levels; less renal insufficiency; and higher body mass indexes, diabe

109 e hypertension, diabetes, heart failure, and renal insufficiency; and were less likely to have insura

110 patients]; OR 2.54, CI 2.06 to 3.14 [severe renal insufficiency]; and OR 1.52, CI 1.32 to 1.76 [mode

111 cluded iron, folate, and B(12) deficiencies, renal insufficiency, anemia of chronic inflammation (ACI

112 age, female gender, diabetes, hypertension, renal insufficiency, anemia, no prior percutaneous coron

113 idence interval [CI] = 3.4-20.6; P < .0001), renal insufficiency (aOR = 2.4; 95% CI = 1.0-5.8; P = .0

114 g requirement for mechanical ventilation and renal insufficiency, are negatively associated with surv

115 clusion of age, electrocardiogram normality, renal insufficiency, arrival mode, chief complaint, admi

116 fined as a GFR <60 mL/min/1.73 m2 and severe renal insufficiency as a GFR <30.

117 2, highest priority shifted to patients with renal insufficiency as a major component of their end-st

118 actory urinary retention, bladder stones, or renal insufficiency as a result of obstructive uropathy.

119 care, when possible, because of the risk of renal insufficiency associated with radical nephrectomy.

120 Patients with at least moderate renal insufficiency at baseline were eliminated from the

121 ad increased risk factors for posttransplant renal insufficiency at study start, relative to patients

122 cular repair (EVAR) in patients with chronic renal insufficiency because of the concern that the cont

123 hy (International Normalized Ratio>2.0), and renal insufficiency (blood urea nitrogen>40 mg/dL) were

124 Excluding from clinical trials patients with renal insufficiency but good performance status on the b

125 a from a control population of patients with renal insufficiency but who did not develop NSF.

126 Renal insufficiency can occur in patients with congenita

127 Worsening renal insufficiency, cardiac arrest with cardiopulmonary

128 1 in an independent testing set, with 74% of renal insufficiency cases among the top two risk quintil

129 eport a form of amyloidosis characterized by renal insufficiency caused by a new apolipoprotein C-III

130 is of participants enrolled into the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic-CRIC Stud

131 The Chronic Renal Insufficiency Cohort (CRIC) is a multicenter, pros

132 m 3,939 participants enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study between 2003 and

133 The Chronic Renal Insufficiency Cohort (CRIC) study enrolled 3939 pa

134 ESS-AKI) study and the subset of the Chronic Renal Insufficiency Cohort (CRIC) study enrollees recrui

135 We followed 1502 participants of the Chronic Renal Insufficiency Cohort (CRIC) Study for a mean of 6.

136 Chronic Renal Insufficiency Cohort (CRIC) Study participants who

137 quality with CKD progression in 431 Chronic Renal Insufficiency Cohort (CRIC) Study participants, of

138 studied 3483 people with CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study recruited from J

139 ng 3093 participants enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study who did not repo

140 a subset of 1214 participants in the Chronic Renal Insufficiency Cohort (CRIC) Study, we determined t

141 In the Chronic Renal Insufficiency Cohort (CRIC) study, we evaluated 29

142 3416 participants with CKD from the Chronic Renal Insufficiency Cohort (CRIC) study.

143 CKD participating in the multicenter Chronic Renal Insufficiency Cohort (CRIC) Study.

144 s of incident hospitalized HF in the Chronic Renal Insufficiency Cohort (CRIC), a multiethnic, multic

145 ages 2 through 4 who enrolled in the Chronic Renal Insufficiency Cohort between June 2003 and Septemb

146 is in 500 subjects with DKD from the Chronic Renal Insufficiency Cohort for DKD phenotypes, including

147 Using 2003-2013 data from the Chronic Renal Insufficiency Cohort Study (3,597 participants wit

148 Using 2003-2013 data from the Chronic Renal Insufficiency Cohort Study (3,597 participants wit

149 in the United States enrolled in the Chronic Renal Insufficiency Cohort Study and followed up from Ma

150 ld to severe CKD who enrolled in the Chronic Renal Insufficiency Cohort Study between June 19, 2003,

151 In our case-cohort study of 894 Chronic Renal Insufficiency Cohort Study participants with diabe

152 The prospective Chronic Renal Insufficiency Cohort study recruited adults with a

153 of 942 participants with CKD in the Chronic Renal Insufficiency Cohort Study who had at least two mG

154 women and 2161 men) enrolled in the Chronic Renal Insufficiency Cohort Study, a large, diverse CKD c

155 In 3655 participants of the Chronic Renal Insufficiency Cohort study, we evaluated the assoc

156 In 1431 participants from the Chronic Renal Insufficiency Cohort study, we measured 25-hydroxy

157 tions among 3487 participants of the Chronic Renal Insufficiency Cohort Study.

158 phate among 2879 participants in the Chronic Renal Insufficiency Cohort Study.

159 tion study among participants in the Chronic Renal Insufficiency Cohort Study.

160 among 3939 patients with CKD in the Chronic Renal Insufficiency Cohort Study.

161 isms [SNPs]) of CAC within the CRIC (Chronic Renal Insufficiency Cohort) study (N = 1,509; 57% Europe

162 The prospective CRIC (Chronic Renal Insufficiency Cohort) study measured the estimated

163 prospective case-cohort study of the Chronic Renal Insufficiency Cohort, we measured FGF23 at two to

164 icated in an independent cohort, the Chronic Renal Insufficiency Cohort.

165 congestive heart failure, hypertension, and renal insufficiency compared with 133,699 patients treat

166 Patients with renal insufficiency, compensated hepatocellular function

167 elop at the time of mild to moderate chronic renal insufficiency (CRI) and progress as renal function

168 o compare health of patients who had chronic renal insufficiency (CRI), were on dialysis, and were po

169 d as an ankle-brachial index (ABI) <0.9, and renal insufficiency, defined as an estimated creatinine

170 nt ESRD outpaced growth in prevalent chronic renal insufficiency, demonstrating that the ESRD epidemi

171 ia, transfusion with packed red blood cells, renal insufficiency, dialysis, or death.

172 s metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular remodeling an

173 he rates of postoperative wound infection or renal insufficiency during this time period, but there w

174 y disease, diabetes mellitus, heart failure, renal insufficiency, ejection fraction, and aortic valve

175 Prevalence of renal insufficiency (estimated glomerular filtration rat

176 resonance (MR) imaging, all 13 patients had renal insufficiency (estimated glomerular filtration rat

177 ve septic shock (4.0-fold, 95% CI 3.58-4.43) renal insufficiency/failure (3.3-fold, 95% CI 2.91-3.65)

178 ve cardiac arrest (OR 2.49, (1.80-3.45)) and renal insufficiency/failure (OR 1.70 (1.32-2.18)).

179 per 1.73 m(2)), 30% (n = 1742) had moderate renal insufficiency (GFR 30 to 59 ml/min per 1.73 m(2)),

180 nal function at 1 year in LT recipients with renal insufficiency [glomerular filtration rate (GFR) <

181 Patients with both HF and renal insufficiency have a poor prognosis.

182 The lack of effect may be related to renal insufficiency, hemodynamic alterations, sodium bal

183 e (HR, 1.88; 95% CI, 1.12-3.16; P=0.02), and renal insufficiency (HR, 2.00; 95% CI, 1.33-3.01; P<0.00

184 after PCI (HR: 2.31; 95% CL: 1.61 to 3.32), renal insufficiency (HR: 2.26; 95% CL: 1.51 to 3.39]), a

185 serum creatinine in a patient with baseline renal insufficiency, hypercholesterolemia, and hypophosp

186 Arterial hypertension, diabetes mellitus, renal insufficiency, hypercholesterolemia, gout, and obe

187 l fibrillation, prior myocardial infarction, renal insufficiency, hypertension, and need for intra-ao

188 as haemolytic anaemia, thrombocytopenia, and renal insufficiency; hypertension and neurological and p

189 Hypertension, renal insufficiency, hypertriglyceridemia, hypercholeste

190 holism, hypoalbuminemia, hyperbilirubinemia, renal insufficiency, hyponatremia, and prothrombin time

191 Moreover, hospitalized AHF patients may have renal insufficiency, hyponatremia, or an inadequate resp

192 For every 1000 adults with chronic renal insufficiency in 1978, 9 new cases of ESRD develop

193 in 1983, but every 1000 adults with chronic renal insufficiency in 1991 produced 16 new cases of ESR

194 f HGF is beneficial in ameliorating diabetic renal insufficiency in mice.

195 tio, 1.70 [95% CI, 1.16-2.48]; P=0.006), and renal insufficiency (incident rate ratio, 1.71 [95% CI,

196 trongly associated with postoperative severe renal insufficiency included: age, gender, white blood c

197 Chronic renal insufficiency inexorably progresses in patients, s

198 diabetes mellitus, sleep apnea, cardiopathy, renal insufficiency, inflammatory bowel disease, immunos

199 ascular hemolysis, cutaneous leg ulceration, renal insufficiency, iron overload, and liver dysfunctio

200 s mellitus (IRR 1.44, 95% CI, 1.14-1.83) and renal insufficiency (IRR 1.36, 95% CI, 1.16-1.61), but l

201 Although renal insufficiency is a recognized risk factor for coro

202 Renal insufficiency is associated with increased morbidi

203 Because renal insufficiency is common among patients with HCV, w

204 merulopathy with proteinuria and progressive renal insufficiency, leading to ESRD.

205 CAD score were age, hyperlipidemia, chronic renal insufficiency, left ventricular function, and plas

206 uding prolonged drug effect in patients with renal insufficiency, limited experience with clinical la

207 rgan systems (proteinuria, thrombocytopenia, renal insufficiency, liver involvement, cerebral symptom

208 include maternal organ dysfunction, such as renal insufficiency, liver involvement, neurological or

209 Noncardiac diagnoses, preexisting renal insufficiency, longer time from onset of the cardi

210 ied 1445 adult lithium-treated patients with renal insufficiency, matched by risk set sampling 1 : 3

211 benefits of using MAR in CABG patients with renal insufficiency may be offset by competing health ri

212 Renal insufficiency may be underrecognized in the genera

213 or bipolar disorder, risk for development of renal insufficiency may discourage their use.

214 ild hepatic synthetic dysfunction and marked renal insufficiency may have higher Model for End-Stage

215 a (mean 10.1 g/d; range 1.3 to 26.3 g/d) and renal insufficiency (mean serum creatinine 3.0 mg/dl; ra

216 ining 17 patients all have developed chronic renal insufficiency (mean serum creatinine, 2.4 mg/dl).

217 were also seen in the frequency of jaundice, renal insufficiency, mechanical ventilation, high-level

218 analysis identified diabetes, septic shock, renal insufficiency, mechanical ventilation, severity of

219 Even in the presence of renal insufficiency, NT-proBNP remained a valuable tool

220 ms of damage (such as subglottic stenosis or renal insufficiency) occur as the direct result of the d

221 However, the impact of milder degrees of renal insufficiency on death rates after lower extremity

222 The effects of renal insufficiency on NT-proBNP among patients with and

223 The impact of intervention for renal insufficiency on the prognosis of UC needs to be f

224 s to better estimate the prognostic value of renal insufficiency on UC, we performed a systematic rev

225 The effect of pre-operative renal insufficiency on urothelial carcinoma (UC) prognos

226 Chronic renal insufficiency, once established, tends to progress

227 duction in models of anemia caused by either renal insufficiency or chronic inflammation with enhance

228 (both in the fibrinogen group); 5 cases with renal insufficiency or failure (3 in the fibrinogen grou

229 cular accident or transient ischemic attack, renal insufficiency or failure, venous thromboembolism,

230 s not require adjustment in mild to moderate renal insufficiency or in any degree of hepatic impairme

231 y when poorly controlled or with concomitant renal insufficiency or obesity.

232 st studies excluded patients with hepatic or renal insufficiency or other serious comorbid conditions

233 static thyroid cancer, elderly patients with renal insufficiency or patients with renal failure.

234 ked less than 5 cigarettes/day, with chronic renal insufficiency or prior cancer, were excluded.

235 und that mutant C57BL/6 mice did not develop renal insufficiency or proteinuria compared to control l

236 per 1.73 m(2)), and 8% (n = 484) had severe renal insufficiency or renal failure (GFR <30 ml/min per

237 retic use (OR, 1.13; 95% CI, 1.07-1.18), and renal insufficiency (OR, 1.11; 95% CI, 1.04-1.17) (multi

238 aneurysmal disease (OR, 9.5; P = 0.075), and renal insufficiency (OR, 7.1; P = 0.003) among its most

239 is, particularly in the setting of diabetes, renal insufficiency, or body mass index <25 kg/m(2).

240 sk patients (>=2 vascular beds affected, HF, renal insufficiency, or diabetes).

241 cially patients who are older, have baseline renal insufficiency, or have hypertension and/or diabete

242 on for congestive heart failure, progressive renal insufficiency, or the need for renal-replacement t

243 tion was similar regardless of hypertension, renal insufficiency, or treatment with ACE inhibitors (p

244 Renal insufficiency, PAH associated with connective tiss

245 is a progressive disorder occurring in some renal insufficiency patients exposed to gadolinium-based

246 lence of obesity, type II diabetes mellitus, renal insufficiency, portal vein thrombosis, and poor pe

247 Renal insufficiency predicts mortality among patients wh

248 concept pilot study in patients (n=40) with renal insufficiency preoperatively (defined as an estima

249 baseline blood pressure, history of chronic renal insufficiency, presence of diabetes mellitus, caus

250 lopurinol dose <300 mg in gout patients with renal insufficiency, QI 2 = uric acid check within 6 mon

251 bypass grafting surgery or in patients with renal insufficiency raises concern.

252 , patients with pre or posttransplant severe renal insufficiency remain more difficult to treat, due

253 Renal insufficiency remained associated with death after

254 Cardiovascular diseases and renal insufficiency represented 16.2% of the comorbiditi

255 al ventilation in 2 of 5 patients (40%), and renal insufficiency requiring hemodialysis in 2 of 5 pat

256 Baseline renal insufficiency (RI) (estimated glomerular filtratio

257 Renal insufficiency (RI) is common after liver transplan

258 ion, metabolic or electrolyte abnormalities, renal insufficiency, sepsis, illness category, and need

259 ber of hemodynamic vulnerability indicators, renal insufficiency, single-ventricle physiology, and co

260 tical for risk standardization: patient age, renal insufficiency, single-ventricle physiology, proced

261 nt outcome benefit in patients with moderate renal insufficiency (stage 3 CKD), whereas there are ver

262 indicate that UC patients with pre-operative renal insufficiency tend to have higher recurrence rates

263 was discharged from hospital with only mild renal insufficiency that did not require renal replaceme

264 history of podagra, hyperuricemia, and mild renal insufficiency, the diagnosis and treatment of gout

265 diate BNP values and with obesity but not in renal insufficiency, the elderly, or patients with edema

266 ty report worse UC outcomes in patients with renal insufficiency, the results between the studies dif

267 d decreases plasma cystatin in patients with renal insufficiency undergoing cardiopulmonary bypass ca

268 roach to improving the care of patients with renal insufficiency undergoing lower extremity amputatio

269 an men, and had more hypertension, diabetes, renal insufficiency, unstable angina, and heart failure,

270 neumonia, ventilator dependence, progressive renal insufficiency, urinary tract infection, stroke, ve

271 best predicted the risk of developing severe renal insufficiency using multiple logistic regression,

272 Thus, 19-nor can suppress the progression of renal insufficiency via mediation of the TGF-beta signal

273 Renal insufficiency was apparent at P21 when proteinuria

274 justment for potential confounders, moderate renal insufficiency was associated with a 37% increased

275 Renal insufficiency was associated with risk factors for

276 onal Kidney Foundation definitions, moderate renal insufficiency was defined as a GFR <60 mL/min/1.73

277 Renal insufficiency was identified using the presence of

278 The association of ABI <0.9 with renal insufficiency was independent of potential confoun

279 Renal insufficiency was independently associated with fu

280 Renal insufficiency was strongly associated with mortali

281 in plasma samples from patients with chronic renal insufficiency were also found in the plasma of hea

282 A noncardiac diagnosis and preexisting renal insufficiency were associated with increased odds

283 accuracy of BNP improved when patients with renal insufficiency were excluded (area under receiver o

284 Patients with chronic renal insufficiency were further stratified into 2 diffe

285 graft dysfunction and the incidence of acute renal insufficiency were higher, and the mean intensive

286 hospital coronary artery bypass grafting and renal insufficiency were independently associated with l

287 with risk factors for CHF, and patients with renal insufficiency were more likely to have CHF (all p

288 the National Kidney Foundation criteria for renal insufficiency when the MDRD equations were used to

289 der and had more often diabetes mellitus and renal insufficiency, whereas they had less often history

290 They also developed renal insufficiency, which became severe only shortly be

291 patients with glomerular disease and chronic renal insufficiency, which might inhibit or potentially

292 can control subjects, and the development of renal insufficiency, which was present in 21% of adults

293 ng renal insufficiency and those who develop renal insufficiency while undergoing stem cell mobilizat

294 teine has been recommended for patients with renal insufficiency who are to receive radiocontrast med

295 Patients with renal insufficiency who received dose modifications were

296 dosing and safety among patients with severe renal insufficiency, will continue to expand options for

297 ice developed hypertension, albuminuria, and renal insufficiency with arteriolar hyalinosis, mesangia

298 rs evaluated was the association of baseline renal insufficiency with future PAD events in the Heart

299 MFR is impaired in patients with renal insufficiency with normal regional perfusion and L

300 lar dysfunction, previous history of stroke, renal insufficiency, women, elderly patients, and those